6978.HK Stock Plunges 19.8% in Pre-Market Trading on May 8

Immunotech Biopharm Ltd (6978.HK) is experiencing a sharp decline in pre-market trading on the Hong Kong Stock Exchange. The 6978.HK stock has dropped 19.8% to HK$0.85, marking one of the most significant single-day losses for the cellular immunotherapy company. This dramatic fall reflects mounting investor concerns about the company’s clinical pipeline and financial performance. The stock has now lost 76.3% over the past year, signaling sustained pressure on the biotech sector. Meyka AI’s real-time market analysis platform is tracking this volatility closely as traders reassess their positions ahead of the market open.

6978.HK Stock Price Collapse and Market Sentiment

The 6978.HK stock opened at HK$0.95 before sliding to a session low of HK$0.81, reflecting intense selling pressure in early trading. Volume surged to 4.52 million shares, more than 4 times the average daily volume of 1.12 million. This elevated trading activity signals panic liquidation among retail and institutional investors.

Technical indicators paint a deeply oversold picture. The Relative Strength Index (RSI) stands at 21.43, well below the 30 threshold that typically signals extreme weakness. The Commodity Channel Index (CCI) at -102.81 confirms severe downward momentum. Williams %R at -99.64 suggests the stock has hit near-term lows, though this does not guarantee a reversal. Track 6978.HK on Meyka for real-time updates on price movements and technical signals.

Financial Deterioration and Valuation Concerns

Immunotech Biopharm’s financial metrics reveal serious operational challenges. The company reported a negative EPS of -0.48 with a PE ratio of -1.92, indicating ongoing losses. Net income per share stands at -0.38, while free cash flow per share is -0.10, showing the company is burning cash.

The balance sheet shows a current ratio of just 0.35, meaning current liabilities exceed current assets by nearly 3 times. This liquidity crisis raises questions about the company’s ability to fund its clinical trials. Working capital is deeply negative at -HK$319.6 million. Debt-to-equity ratio of -31.6 reflects negative shareholder equity, a red flag for long-term viability. The company’s market cap has eroded to HK$472.4 million, down from historical highs of HK$5.83 per share.

Clinical Pipeline and Business Model Risks

Immunotech Biopharm focuses on T-cell immunotherapy products for cancer treatment in China. The core product, EAL, is in Phase II clinical trials for liver cancer prevention. The company also develops 6B11-OCIK injection (Phase I for ovarian cancer), CAR-T-19 for leukemia, and TCR-T cell series for solid tumors.

However, the company generates zero revenue currently, relying entirely on cash reserves to fund development. With 1,540 full-time employees, operating expenses remain substantial. The lack of commercialized products combined with negative cash flow creates existential risk. Earnings are scheduled for announcement on August 21, 2026, which may provide clarity on funding runway and trial progress.

Meyka AI Rating and Forward Outlook

Meyka AI rates 6978.HK with a grade of B and a HOLD recommendation, with a total score of 65.5 out of 100. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects mixed signals: while the company operates in the high-growth biotech sector, its financial distress and negative cash flow create significant downside risk.

Meyka AI’s forecast model projects a yearly price target of HK$4.14, implying 387% upside from current levels. However, this assumes successful clinical trial outcomes and future commercialization. Forecasts are model-based projections and not guarantees. The company faces a critical juncture: success in clinical trials could drive recovery, but funding constraints may force dilutive capital raises or strategic partnerships.

Final Thoughts

Immunotech Biopharm’s 19.8% pre-market decline to HK$0.85 reflects investor concerns over liquidity and clinical trial uncertainty. The company’s negative cash flow and zero revenue create significant financial risk. While cellular immunotherapy offers long-term potential, near-term survival depends on successful trials and capital availability. The stock remains highly speculative for risk-tolerant investors only. Monitor August earnings for funding and trial updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.